H.C. Wainwright Remains Bullish on Precigen (PGEN)

Precigen, Inc. (NASDAQ:PGEN) is one of the top strong buy stocks under $5 to buy now. H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Precigen, Inc. (NASDAQ:PGEN) on August 19, keeping the associated price target the same at $8.50.

The analyst supported his positive rating with several factors, including the recent FDA approval of Papzimeos that surpassed expectations with its earlier-than-anticipated announcement.

He added that the approval encompasses a broad indication for recurrent respiratory papillomatosis, proving beneficial to around 27,000 adult American patients.

The label is favorable, including a broad indication and positive durability data, bolstering the drug’s market potential, according to the analyst.

Ramakanth also stated that Papzimeos has a promising financial outlook, with estimated sales of around $15 million in Q4 2025.

Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company involved in the research and development of synthetic biology technologies. The company’s operations are divided into the following segments: Biopharmaceuticals, Exemplar, and Trans Ova.

While we acknowledge the potential of PGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.